131 related articles for article (PubMed ID: 12843152)
1. Circulating ghrelin levels in patients with pancreatic and gastrointestinal neuroendocrine tumors: identification of one pancreatic ghrelinoma.
Corbetta S; Peracchi M; Cappiello V; Lania A; Lauri E; Vago L; Beck-Peccoz P; Spada A
J Clin Endocrinol Metab; 2003 Jul; 88(7):3117-20. PubMed ID: 12843152
[TBL] [Abstract][Full Text] [Related]
2. Malignant gastric ghrelinoma with hyperghrelinemia.
Tsolakis AV; Portela-Gomes GM; Stridsberg M; Grimelius L; Sundin A; Eriksson BK; Oberg KE; Janson ET
J Clin Endocrinol Metab; 2004 Aug; 89(8):3739-44. PubMed ID: 15292299
[TBL] [Abstract][Full Text] [Related]
3. 7B2, a possible marker for nonfunctioning pancreatic islet cell tumor.
Iguchi H; Yasuda D; Yamada Y; Funakoshi A; Wakasugi H; Bloom SR; Chretien M
Horm Metab Res; 1991 Oct; 23(10):486-9. PubMed ID: 1662184
[TBL] [Abstract][Full Text] [Related]
4. Adrenomedullin is a novel marker of tumor progression in neuroendocrine carcinomas.
Pavel ME; Hoppe S; Papadopoulos T; Linder V; Mohr B; Hahn EG; Lohmann T; Schuppan D
Horm Metab Res; 2006 Feb; 38(2):112-8. PubMed ID: 16523412
[TBL] [Abstract][Full Text] [Related]
5. Islet amyloid polypeptide (IAPP) in patients with neuroendocrine tumours.
Stridsberg M; Eriksson B; Lundqvist G; Skogseid B; Wilander E; Oberg K
Regul Pept; 1995 Jan; 55(2):119-31. PubMed ID: 7754100
[TBL] [Abstract][Full Text] [Related]
6. Suppression of primary and secondary peptides with somatostatin analog in the therapy of functional endocrine tumors.
Woltering EA; Mozell EJ; O'Dorisio TM; Fletcher WS; Howe B
Surg Gynecol Obstet; 1988 Dec; 167(6):453-62. PubMed ID: 2460958
[TBL] [Abstract][Full Text] [Related]
7. Surgical experience with functioning pancreatic neuroendocrine tumors.
Matthews BD; Smith TI; Kercher KW; Holder WD; Heniford BT
Am Surg; 2002 Aug; 68(8):660-5; discussion 665-6. PubMed ID: 12206598
[TBL] [Abstract][Full Text] [Related]
8. Ghrelin-producing endocrine tumors of the stomach and intestine.
Papotti M; Cassoni P; Volante M; Deghenghi R; Muccioli G; Ghigo E
J Clin Endocrinol Metab; 2001 Oct; 86(10):5052-9. PubMed ID: 11600584
[TBL] [Abstract][Full Text] [Related]
9. Ghrelin in human medullary thyroid carcinomas.
Morpurgo PS; Cappiello V; Verga U; Vicentini L; Vaghi I; Lauri E; Nebuloni M; Beck-Peccoz P; Spada A
Clin Endocrinol (Oxf); 2005 Oct; 63(4):437-41. PubMed ID: 16181236
[TBL] [Abstract][Full Text] [Related]
10. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.
Nikou GC; Lygidakis NJ; Toubanakis C; Pavlatos S; Tseleni-Balafouta S; Giannatou E; Mallas E; Safioleas M
Hepatogastroenterology; 2005; 52(63):731-41. PubMed ID: 15966194
[TBL] [Abstract][Full Text] [Related]
11. [The diagnostic value of plasma chromogranin A in neuroendocrine tumors].
Yang XO; Li JN; Qian JM; Yang H; Chen Q; Lu L
Zhonghua Nei Ke Za Zhi; 2011 Feb; 50(2):124-7. PubMed ID: 21418832
[TBL] [Abstract][Full Text] [Related]
12. Gastrointestinal neuroendocrine tumors.
Delcore R; Friesen SR
J Am Coll Surg; 1994 Feb; 178(2):187-211. PubMed ID: 8173736
[TBL] [Abstract][Full Text] [Related]
13. Use of octreotide in the treatment of digestive neuroendocrine tumours. Seven year experience in 20 cases including 9 cases of metastatic midgut carcinoid and 5 cases of metastatic gastrinoma.
Fiasse R; Pauwels S; Rahier J; Jamar F; Ketelslegers JM; Hassoun A; de Longueville M
Acta Gastroenterol Belg; 1993; 56(3-4):279-91. PubMed ID: 8266771
[TBL] [Abstract][Full Text] [Related]
14. Co-expression of ghrelin and its receptor in pancreatic endocrine tumours.
Ekeblad S; Lejonklou MH; Grimfjärd P; Johansson T; Eriksson B; Grimelius L; Stridsberg M; Stålberg P; Skogseid B
Clin Endocrinol (Oxf); 2007 Jan; 66(1):115-22. PubMed ID: 17201810
[TBL] [Abstract][Full Text] [Related]
15. Ghrelin expression in islet cell tumors: augmented expression of ghrelin in a case of glucagonoma with multiple endocrine neoplasm type I.
Iwakura H; Hosoda K; Doi R; Komoto I; Nishimura H; Son C; Fujikura J; Tomita T; Takaya K; Ogawa Y; Hayashi T; Inoue G; Akamizu T; Hosoda H; Kojima M; Kangawa K; Imamura M; Nakao K
J Clin Endocrinol Metab; 2002 Nov; 87(11):4885-8. PubMed ID: 12414844
[TBL] [Abstract][Full Text] [Related]
16. [Chromogranin A and neuroendocrine tumors].
Díaz Pérez JÁ; Currás Freixes M
Endocrinol Nutr; 2013; 60(7):386-95. PubMed ID: 23271036
[TBL] [Abstract][Full Text] [Related]
17. Effects of sandostatin on plasma chromogranin-A levels in neuroendocrine tumors.
Moattari AR; Deftos LJ; Vinik AI
J Clin Endocrinol Metab; 1989 Oct; 69(4):902-5. PubMed ID: 2778040
[TBL] [Abstract][Full Text] [Related]
18. Chromogranin A as a biochemical marker for the management of neuroendocrine tumors: a multicenter study developed in Argentina.
Belli SH; Oneto A; Aranda C; O'Connor JM; Domenichini E; Roca E; Méndez G; Bestani MC; Parma P; Giacomi N; Marmissolle F
Acta Gastroenterol Latinoam; 2009 Sep; 39(3):184-9. PubMed ID: 19845257
[TBL] [Abstract][Full Text] [Related]
19. [Use of octreotide in the treatment of digestive endocrine tumors. A French multicenter study].
Blanchin M; James-Deidier A; Chaumet-Riffaud PD; Chayvialle JA
Presse Med; 1992 Apr; 21(15):697-702. PubMed ID: 1376476
[TBL] [Abstract][Full Text] [Related]
20. Ghrelin expression in neuroendocrine tumours of the gastrointestinal tract with multiple endocrine neoplasia type 1.
Raffel A; Krausch M; Cupisti K; Gerharz CD; Eisenberger CF; Knoefel WT
Horm Metab Res; 2005 Oct; 37(10):653-5. PubMed ID: 16278790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
